Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

24 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Vivitrol Articles

Alkermes shrugs off Bydureon and focuses on pipeline, company reveals in interview with EP Vantage

15 November 2010

US FDA approves Alkermes’ Vivitrol to treat opioid-dependent patients and orphan status for PharmaLink’s Nefecon

13 October 2010

US FDA advisories say no to Arena/Eisai’s obesity drug lorcaserin; back new use for Alkermes’ Vivitrol

17 September 2010

Alkermes completes Ph IIIb Vivitrol enrollment

22 April 2009

Stock Commentary - New York week to Feb 16, 2009

23 February 2009

Alkermes regains the rights to Vivitrol from Cephalon along with $120M in revenue

8 December 2008

Alkermes/J&J's Vivitrol approved in Russia

11 August 2008

Reliant sale boosts Alkermes 3rd-qtr EPS

18 February 2008

Cilag licenses Alkermes

14 January 2008

Alkermes sees fiscal 1st-qtr net income of $8.7M

13 August 2007

Alkermes submits Vivitrol MAA in UK and Germany

9 April 2007

Alkermes reports $3M 4th-qtr 2006 net income

19 February 2007

Alkermes/Cephalon: COMBINE study supports use of Vivitrol

8 May 2006

FDA approves Vivitrol for alcohol dependency

24 April 2006

Burrill: US biotech racked up impressive quarter to close 2005 in record fashion

16 January 2006

Stock Commentary - New York week to Jan 9

9 January 2006

Vivitrol gains FDA approvable letter

9 January 2006

Showing 1-17 of 17 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • Italy's pharma market slump set to continue, warns GlobalData
  • US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • Italy's pharma market slump set to continue, warns GlobalData

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS